Wells Fargo
GLUE icon

Wells Fargo’s Monte Rosa Therapeutics GLUE Stock Holding History

Wells Fargo’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$382K Sell
23,211
-29,377
-56% -$562K ﹤0.01% 4303
2025
Q4 		$825K Buy
52,588
+16,308
+45% +$220K ﹤0.01% 4117
2025
Q3 		$269K Buy
36,280
+2,583
+8% +$13.7K ﹤0.01% 4753
2025
Q2 		$152K Buy
33,697
+5,142
+18% +$22.9K ﹤0.01% 4931
2025
Q1 		$132K Sell
28,555
-41,607
-59% -$255K ﹤0.01% 4947
2024
Q4 		$487K Buy
70,162
+47,952
+216% +$360K ﹤0.01% 4201
2024
Q3 		$118K Buy
22,210
+5,902
+36% +$29.8K ﹤0.01% 4924
2024
Q2 		$61K Buy
16,308
+3,089
+23% +$15.8K ﹤0.01% 5219
2024
Q1 		$93.2K Buy
13,219
+1,336
+11% +$7.92K ﹤0.01% 4933
2023
Q4 		$67.1K Buy
11,883
+2,127
+22% +$8.34K ﹤0.01% 5147
2023
Q3 		$46.7K Sell
9,756
-3,894
-29% -$25.1K ﹤0.01% 5214
2023
Q2 		$93.5K Buy
13,650
+8,133
+147% +$52.6K ﹤0.01% 5084
2023
Q1 		$43K Buy
+5,517
New +$38.4K ﹤0.01% 5243
2022
Q4 		– Sell
-80
Closed -$1K – 7559
2022
Q3 		$1K Sell
80
-173
-68% -$1.59K ﹤0.01% 6346
2022
Q2 		$2K Sell
253
-15,491
-98% -$156K ﹤0.01% 6317
2022
Q1 		$221K Sell
15,744
-36
-0.2% -$500 ﹤0.01% 4922
2021
Q4 		$322K Buy
15,780
+15,723
+27,584% +$329K ﹤0.01% 4998
2021
Q3 		$1K Buy
+57
New +$1.63K ﹤0.01% 6707

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Wells Fargo's GLUE Position: Q1 2026 in Review

Wells Fargo reduced its Monte Rosa Therapeutics (GLUE) stake by 56% in Q1 2026, selling an estimated $562K and leaving 23,211 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #4303.

Wells Fargo first reported a position in GLUE in Q3 2021 and has held it in 18 quarters since. The position peaked at $825K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Wells Fargo held 23,211 shares of Monte Rosa Therapeutics worth $382K as of Q1 2026.
  • Wells Fargo sold 29,377 Monte Rosa Therapeutics shares in Q1 2026, an estimated $562K.
  • Monte Rosa Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4303 holding.
  • Wells Fargo first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Wells Fargo's Monte Rosa Therapeutics position peaked at $825K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.